Gene · 8030
Papers1,913
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 1,913
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Improved artificial intelligence discrimination of minor histological populations by supplementing with color-adjusted images. | Sci Rep | 2023 | 37925580 | PubTator, text mining | PubMed |
| Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer. | Support Care Cancer | 2023 | 37924363 | PubTator, text mining | PubMed |
| Epidemiology of musculoskeletal injury in military recruits: a systematic review and meta-analysis. | BMC Sports Sci Med Rehabil | 2023 | 37898757 | PubTator, text mining | PubMed |
| Difficult-to-Treat Rejections in Kidney Transplant Recipients: Our Experience with Everolimus-Based Quadruple Maintenance Therapy. | J Clin Med | 2023 | 37892805 | PubTator, text mining | PubMed |
| Molecular Analysis of Biliary Tract Cancers with the Custom 3' RACE-Based NGS Panel. | Diagnostics (Basel) | 2023 | 37891989 | PubTator, text mining | PubMed |
| Genotype-phenotype spectrum and prognosis of early-onset Marfan syndrome. | BMC Pediatr | 2023 | 37891508 | PubTator, text mining | PubMed |
| RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis. | Endocr Relat Cancer | 2023 | 37882481 | PubTator, text mining | PubMed |
| Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer. | ESMO Open | 2023 | 37879236 | PubTator, text mining | PubMed |
| Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report. | Front Oncol | 2023 | 37876974 | PubTator, text mining | PubMed |
| First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. | N Engl J Med | 2023 | 37870973 | PubTator, text mining | PubMed |
| Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors. | Front Endocrinol (Lausanne) | 2023 | 37867524 | PubTator, text mining | PubMed |
| First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis. | Transl Lung Cancer Res | 2023 | 37854153 | PubTator, text mining | PubMed |
| Diagnostic clues for hyalinizing trabecular tumor on fine needle aspiration cytology. | Cytojournal | 2023 | 37810443 | PubTator, text mining | PubMed |
Uncovering the immune microenvironment and molecular subtypes of hepatitis B-related liver cirrhosis and developing stable a diagnostic differential model by machine learning and artificial neural networks. | Front Mol Biosci | 2023 | 37808522 | PubTator, text mining | PubMed |
| ALK fusions in the pan-cancer setting: another tumor-agnostic target? | NPJ Precis Oncol | 2023 | 37773318 | PubTator, text mining | PubMed |
| Defining the condensate landscape of fusion oncoproteins. | Nat Commun | 2023 | 37770423 | PubTator, text mining | PubMed |
| Indeterminate Thyroid Nodules: From Cytology to Molecular Testing. | Diagnostics (Basel) | 2023 | 37761374 | PubTator, text mining | PubMed |
| FGFR families: biological functions and therapeutic interventions in tumors. | MedComm (2020) | 2023 | 37750089 | PubTator, text mining | PubMed |
| Homeostatic role of B-1 cells in tissue immunity. | Front Immunol | 2023 | 37744333 | PubTator, text mining | PubMed |
| Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification. | PeerJ | 2023 | 37744220 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8030/papers?page=9